Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study
Authors' conclusion
Overall, our data suggest that ixazomib induces overflow remodeling-based bone formation by decreasing the level of bone resorption and promoting longer bone formation events, making it a potentially valuable candidate for future maintenance treatment.
Study context
- Population
- Patients with multiple myeloma in stable disease, not receiving antimyeloma treatment for ≥3 months, with ≥2 osteolytic lesions
- Participants
- 30 patients
- Outcome
- Effect of ixazomib on bone formation and bone microstructure
- Follow-up
- After three treatment cycles
Methodological details3-month results, single-center, phase II
- 3-month results
- Single-center
- Phase II
Main finding
As reported in the abstract
after three treatment cycles
- Bone remodeling biomarkers suggested an early ixazomib-induced decrease in bone resorption
- NaF-PET: unchanged bone formation ratios
- Bone biopsies: significant increase in bone volume per total volume after treatment
- Unchanged osteoclast number and COLL1A1High-expressing osteoblasts on bone surfaces
- Significantly more superficial bone structural units enlarged (>200,000 μm²) after treatment; shape distribution significantly different from baseline
Original publication
Increased Bone Volume by Ixazomib in Multiple Myeloma: 3-Month Results from an Open Label Phase 2 Study. J Bone Miner Res. Published 27 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →